CareDx, Miromatrix Collaborate on Bioengineered Organs Research

CareDx Inc. and Miromatrix Medical Inc. have forged an exclusive partnership to investigate ways to develop fully transplantable human bioengineered organs.
 
CareDx intends to create a testing solution for Miromatrix to use in pre-clinical animal models and will be the exclusive provider of donor-derived cell-free DNA (dd-cfDNA) testing services for use in human clinical studies to non-invasively assess acute allograft rejection in Miromatrix’s pipeline of human bioengineered organs.
 
“We are committed to being at the forefront of driving the next wave of innovation to address the organ supply shortage in transplantation through this collaboration with Miromatrix. We hope one day that bioengineered organs will become a reality for the thousands of patients waiting for a life-saving organ,” CareDx President/CEO Reg Seeto said. “We are proud to partner with Miromatrix, a leader at the forefront of human bioengineered organ development as they apply our expertise to advance their clinical pipeline.”

More than 100,000 people (estimated) in the United States are waiting for an organ transplant,¹ but only slightly more than half of them are expected to receive an organ within five years.² An estimated 17 people die each day waiting for an organ transplant.¹
 
“CareDx is at the leading edge of transplant innovation and has been instrumental in driving paradigm shifts in clinical practice through their non-invasive testing services which are widely used by leading organ transplant centers across the U.S.,” Miromatrix CEO Jeff Ross Ph.D., stated. “Our partnership with CareDx allows us to tap into their expertise in ways that may help us accelerate our momentum as we drive the next wave of innovation with bioengineered alternatives for use in human organ transplants.”
 
Headquartered in Brisbane, Calif., CareDx is a precision medicine solutions company that develops and commercializes clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and provides genomics-based information for transplant patients. 
 
Miromatrix Medical Inc. is a life sciences company pioneering technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix has developed a proprietary perfusion technology platform for bioengineering organs to address the shortage of available human organs. Miromatrix’s initial development focus is on human livers and kidneys. 
 
References
¹ Health Resources and Services Administration: Organ Donation Statistics. 
² United Network for Organ Sharing: Waiting for your transplant